HLVX vs. FULC, ITOS, RVNC, ETON, RZLT, CYRX, ERAS, VIGL, CKPT, and TECX
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Eton Pharmaceuticals (ETON), Rezolute (RZLT), CryoPort (CYRX), Erasca (ERAS), Vigil Neuroscience (VIGL), Checkpoint Therapeutics (CKPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry.
HilleVax vs. Its Competitors
Fulcrum Therapeutics (NASDAQ:FULC) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
Fulcrum Therapeutics currently has a consensus price target of $6.29, indicating a potential downside of 8.93%. HilleVax has a consensus price target of $3.00, indicating a potential upside of 43.20%. Given HilleVax's higher possible upside, analysts plainly believe HilleVax is more favorable than Fulcrum Therapeutics.
Fulcrum Therapeutics has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
In the previous week, Fulcrum Therapeutics had 1 more articles in the media than HilleVax. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 1 mentions for HilleVax. HilleVax's average media sentiment score of 1.89 beat Fulcrum Therapeutics' score of 0.41 indicating that HilleVax is being referred to more favorably in the news media.
Fulcrum Therapeutics has higher revenue and earnings than HilleVax. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 24.9% of HilleVax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Fulcrum Therapeutics' return on equity of -0.20% beat HilleVax's return on equity.
Summary
Fulcrum Therapeutics beats HilleVax on 11 of the 15 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
This page (NASDAQ:HLVX) was last updated on 7/2/2025 by MarketBeat.com Staff
